Table 4.
Correlations between BLM, HDGF expression and clinicopathological characteristics of PCa patients
| Clinicopathological characteristics | N | BLM | X2 | P value | HDGF | X2 | P value | ||
|---|---|---|---|---|---|---|---|---|---|
| Positive (%) | Negative (%) | Positive (%) | Negative (%) | ||||||
| Age (years) | |||||||||
| ≤ 69 | 24 | 16(66.7) | 8(33.3) | 2.204 | 0.138 | 17(70.8) | 7(29.1) | 0.031 | 0.86 |
| > 69 | 26 | 22(84.6) | 4(16.4) | 19(73.1) | 7(26.9) | ||||
| T status | |||||||||
| T1–T2 | 30 | 20(70.0) | 10(30.0) | 3.582 | 0.058 | 19(63.3) | 11(36.7) | 2.794 | 0.095 |
| T3–T4 | 20 | 18(95.0) | 2(5.0) | 17(85.0) | 3(15.0) | ||||
| Clinical stage | |||||||||
| I–II | 30 | 20(70.0) | 10(30.0) | 3.5828 | 0.058 | 19(63.3) | 11(36.7) | 2.794 | 0.095 |
| III–IV | 20 | 18(95.0) | 2(5.0) | 17(85.0) | 3(15.0) | ||||
| Gleason score | |||||||||
| < 7 | 13 | 5(38.5) | 8(61.5) | 13.572 | 0.000 | 6(46.2) | 7(53.8) | 5.821 | 0.016 |
| ≥ 7 | 37 | 33(89.2) | 4(10.8) | 30(81.1) | 7(18.9) | ||||
| Gleason grade | |||||||||
| 1–3 | 21 | 11(52.4) | 10(47.6) | 11.074 | 0.001 | 11(52.4) | 10(47.6) | 6.913 | 0.009 |
| 4–5 | 29 | 27(93.1) | 2(6.9) | 25(86.2) | 4(13.8) | ||||
| N-regional lymph nodes | |||||||||
| N0 | 44 | 33(77.5) | 11(25.0) | 1.923 | 0.166 | 31(70.5) | 13(29.5) | 0.434 | 0.510 |
| N1 | 6 | 6(100.0) | 0(0.0) | 5(83.3) | 1(16.7) | ||||
| M-Distant metastasis | |||||||||
| M0 | 49 | 38(77.6) | 11(22.4) | 0.288 | 0.592 | 35(71.4) | 14(28.6) | 0.397 | 0.529 |
| M1 | 1 | 1(100.0) | 0(0.0) | 1(100.0) | 0(0.0) | ||||
P value is from χ2-test